-
2024-514693-47-01
11
2025-10-28
EGFR mutated locally advanced or metastatic non-small cell lung cancer
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-517432-21-00
4
2025-05-30
Gynecological Cancers
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-516068-27-01
5
2025-04-10
cardiopulmonary resuscitation
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav